This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Antidiabetics Market

Market Insights on Antidiabetics covering sales outlook, demand forecast & up-to-date key trends

Antidiabetics Market by Product, Patient Population, Route of Administration & Region - Forecast 2022 – 2032

Antidiabetics Market Outlook (2022-2032)

[311 Pages Report] Exhibiting a Y-o-Y growth rate of 10.9%, the global antidiabetics market is expected to garner US$ 89.2 Billion in 2022, against US$ 80.4 Billion in 2021. The industry is estimated to reach US$ 223 Billion, displaying a CAGR of 9.6% during the assessment period from 2022- to 2032. The growing prevalence of diabetes across the globe is expected to be the most significant factor driving the global antidiabetics market during the stint of 2022 to 2032.

“Increasing diabetic cases across the globe with the rising geriatric population is expected to drive the market. Also, the rapid development of healthcare infrastructure in developing countries can further expand the market size in the forthcoming period.”

Attributes

Details

Global Antidiabetics Market CAGR (2022-to 2032)

9.6%

Global Antidiabetics Market Size (2022)

US$ 89.2 Billion

Global Antidiabetics Market Size (2032)

US$ 223 Billion

As per International Diabetes Federation, the global diabetes incidence is anticipated to increase from 366 million in 2011 to 552 million by 2030. Such a significant rise in diabetic patients is expected to positively impact the market in the coming time. Other factors such as; the growing geriatric population, rising cases of obesity, and the development of new products are expected to benefit the market in the forecast period. For instance, in January 2022, Novo Nordisk, announced the launch of oral semaglutide in India for the treatment of Type 2 diabetes. Such initiatives taken by players to strengthen their reach in the global market are projected to benefit the market in the assessment period.

Additionally, the growing approval for antidiabetic drugs and a strong pipeline for antidiabetics are expected to offer significant opportunities for market expansion. The antidiabetic pipeline comprises SCO-094, Tirzepatide, Volagidemab, CT-388, GX G6, ORMD-0801, and others. Moreover, the increasing number of drug approvals by the FDA is projected to offer significant opportunities to the players. The number of therapeutic alternatives to treat T2DM is rising and there are about 60 drugs approved by the FDA. Further, there are approximately 100 additional antidiabetic agents being evaluated in clinical trials. Also, the standard treatments of insulin therapy and metformin, there are new drug combinations containing metformin, SGLT2 inhibitors, and dipeptidyl peptidase-4 (DPP4). Such factors are anticipated to benefit the market notably in the forecast period.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Factors Driving the Global Antidiabetics Market?

Increasing investment in drug development to tackle the growing incidences of diabetes is expected to propel the industry’s expansion in the forecast period. As per the European Society of Cardiology, the diabetic population is likely to reach 628.6 million by 2045. Therefore, there has been growing advancement in antidiabetic drugs that has resulted in growing success rates and reduced complications. For instance, in May 2022, the Food and Drug Administration approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar.

Antidiabetics Market Download Report Brochure

In addition, rising glucose intolerance with increasing age is expected to enhance the demand for antidiabetics amongst the geriatric population. Also, the expanding geriatric population is expected to generate significant demand for antidiabetics. With advancing age, the prevalence of Type 2 diabetes is increasing along with the enhanced risk of vascular diseases, coronary heart diseases, and stroke. Therefore, in order to regulate comorbidities along with the advancing age of baby boomers, the market is expected to benefit in the forecast time.

Furthermore, increasing investments in research and development by players are projected to support the market growth in the forecast period. In 2019, Glenmark launched an oral anti-diabetic drug Remogliflozin in India. The drug is effective in treating adults with Type-2 diabetes mellitus.

What are the Contemporary Opportunities in the Global Antidiabetics Market?

The rapid adoption of insulin pumps amongst diabetic patients is expected to offer significant market opportunities in the forecast period. The development of advanced pumps powered by smart technologies such as; AI and ML are expected to offer remunerative opportunities to the market. In July 2021, Ypsomed AG expanded the range of features of the mylife YpsoPump system. The app-based deployment of the Dexcom G6 Continuous Glucose Monitoring (CGM) System allows people with diabetes to manage their therapy through their smartphones.

Also, product approvals with the presence of a robust pipeline are projected to be another remunerative opportunity for market growth in the forecast period. The ongoing development in insulin pumps is likely to augment the market size and pose a lucrative opportunity. For instance, Tandem Diabetes, Inc. focuses on developing delivery device solutions to meet the requirement of people living with Type 1 and Type 2 diabetes. Mobi, t: slim X3, and Mobi: Tubeless are some of the products in the pipeline of Tandem Diabetes Care, Inc.

The growing awareness about the advanced insulin pumps among diabetic patients and the benefits associated with disease management is expected to boost the market growth in the assessment period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Restraining Factors in the Global Antidiabetics Market?

High costs associated with the insulin pumps are expected to limit the market growth in the forecast period. As per an article published by Mdedge, insulin pumps are more expensive than daily injections. The estimated cost difference is 30%. The cost of these pumps involves additional costs of consumables such as batteries, sensors, and others. Moreover, lack of awareness about the treatment methods available and poor reimbursement policies in developing countries are other factors hindering the market growth in the assessment period.

However, clinical benefits offered by insulin pumps along with advanced features such as; integrated CGM sensors, smartphone connectivity, and other features, are expected to create the popularity of these pumps among healthcare professionals and patients suffering from diabetes.

Comparative View of Adjacent Antidiabetics Markets

Global Antidiabetics Market:

Attributes

Global Antidiabetics Market

CAGR (2022- to 2032)

9.6%

Market Value (2032)

US$ 223 Billion

Growth Factor

Increasing investment in drug development to tackle the growing incidences of diabetes is anticipated to augment the market size in the forecast period.

Opportunities

The development of advanced pumps powered by smart technologies such as; AI and ML are expected to offer lucrative opportunities for market growth in the forecast period.

Global Diabetes Care Devices Market:

Attributes

Global Diabetes Care Devices Market

CAGR (2022- to 2032)

4.5%

Market Value (2032)

US$ 50 Billion

Growth Factor

The growing prevalence of diabetes and the rising number of programs initiated by various healthcare organizations are expected to benefit the market during the forecast period.

Opportunities

Ongoing technological innovations and development are expected to offer various significant opportunities for expansion in the forecast period.

Global Insulin Pump Market:

Attributes

Global Insulin Pump Market

CAGR (2022- to 2032)

12.02%

Market Value (2032)

US$ 14 Billion

Growth Factor

The growing prevalence of diabetes, especially type 1 is expected to act as a significant driver of the market during the forecast period.

Opportunities

Integration of smart technologies in insulin pumps is projected to offer significant market opportunities in the forecast period.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Segmental Analysis of Antidiabetics Market

By Product, which Category is expected to dominate the Global Market?

Insulin Antidiabetics to be Most Sought After across the Coming Decade

As per the analysis, the global antidiabetics market, by product, is anticipated to be dominated by the Insulin segment. The segment is predicted to exhibit a CAGR of 9.4% in the assessment period. The growth of the segment can be attributed to the introduction of new products and the number of products in the pipeline.

Which is the Most Preferred Route of Administration of Antidiabetics?

Oral Ingestion of Antidiabetics to be Most Popular

Based on the route of administration, the oral segment is projected to lead the market in the forecast period. The segment is anticipated to expand at a growth rate of 9.5% in the assessment period. The development of the segment can be attributed to the introduction of new drugs and also the rapid rise in the Type-2 diabetes population.

Region-wise Analysis of Antidiabetics Market

How will Growth Prospects Unravel across North America?

Availability of a Wide Range of Insulin Drugs Propelling Expansion

As per the analysis, the global antidiabetics market is anticipated to be dominated by North America. In the region, the U.S is predicted to dominate the market in the forecast period. The region is estimated at US$ 79.6 Billion.

The growth of the market can be attributed to the penetration of modern insulin products that are long-lasting, rapid-acting insulin, and DPP-4 drugs such as Onglyza, Januvia, and Nesina. Also, approvals by FDA are expected to propel the market growth in the forecast period.

For instance, in May 2022, Eli Lilly obtained FDA approval for a diabetes drug that may also help with obesity. In addition, increased patient awareness levels, high healthcare expenditure, and reimbursement framework are other factors driving the industry growth in the forecast period. Such factors are expected to develop the market in the region.

Will Europe & APAC emerge as an Attractive Investment Hotspot for Antidiabetics?

High Diabetes Prevalence Rates driving Consumption across the U.K and China

Europe is anticipated to witness decent growth in the forecast period. The U.K is estimated at US$ 9.2 Billion. As per WHO, about 60 million people have been infected with the disease across Europe. The surging case across the region is projected to be the most important factor driving the market in the forecast period.

Country

Estimated CAGR

U.S

9.4%

U.K

8.3%

China

8.9%

Japan

7.9%

South Korea

7.5%

APAC is anticipated to be the most lucrative market during the forecast period. China is anticipated to lead the market in the forecast period. The country is estimated at US$ 16 Billion. Other anticipated lucrative countries are South Korea and Japan. Expansion of the regional market can be attributed to the growing prevalence of diabetes amongst the expanding geriatric population. Rising cases of diabetes can be attributed to the growing urbanization and adoption of a sedentary lifestyle. Also, the presence of developing countries is likely to aid in expanding the regional market growth.

Competitive Landscape

Key players in the global antidiabetic market include Bayer Corporation, AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Bristol-Myers Squibb. Recent developments in the industry are:

  • In May 2022, the Food and Drug Administration approved a new drug for people with Type 2 diabetes. The drug, Tirzepatide is a once-a-week injection that helps people in managing their blood glucose levels and lessen food intake.
  • In May 2021, F. Hoffmann-La Roche Ltd., launched mySugar Pump Control under the mySugr app. mySugr Pump Control enables patients to control insulin pumps via smartphone to import and view the data status.

Key Segments Profiled in the Global Antidiabetics Market Study

Antidiabetics Market by Product:

  • Insulin-based Antidiabetics
    • Rapid-Acting Analog
    • Long-Acting Analog
    • Premixed Insulin
    • Short-Acting Analog
    • Intermediate-Acting Insulin
  • Antidiabetics Drug Class
    • Alpha-Glucosidases Inhibitors
    • Biguanides
    • Sulphonylureas
    • GLP-1 (Glucagon-like peptide) Agonists
    • DPP-IV (Dipeptidyl Peptidase) Inhibitors
    • Meglitinides
    • SGLT-II (Sodium-Glucose Transport Proteins) Inhibitors
    • Thiazolidinedione

Antidiabetics Market by Patient Population:

  • Antidiabetics for Pediatrics
  • Antidiabetics for Adults
  • Antidiabetics for Geriatrics

Antidiabetics Market by Route of Administration:

  • Antidiabetics Administration through Insulin Syringes/ Insulin Pens
  • Antidiabetics Administration through Insulin Pumps
  • Intravenous Antidiabetics Infusion
  • Oral Antidiabetics Administration
  • Other Routes of Antidiabetics Administration

Antidiabetics Market by Region:

  • North America Antidiabetics Market
  • Europe Antidiabetics Market
  • APAC Antidiabetics Market
  • MEA Antidiabetics Market
  • Latin America Antidiabetics Market

Frequently Asked Questions

The global antidiabetics market is estimated at US$ 89.2 Billion in 2022.

By product, insulin-based antidiabetics is projected to witness a CAGR of 9.4% by 2032.

Antidiabetic sales in South Korea are anticipated to reach US$ 8 Billion by 2032.

The expected market value from 2022- to 2032 is US$ 223 Billion.

The market in the U.S is anticipated to garner US$ 79.6 Billion by 2032.

China is projected to document a value CAGR of 8.9% by 2032 with regard to antidiabetic sales.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook 

    1.2. Summary of Statistics

    1.3. Key Market Characteristics & Attributes

    1.4. FMI Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy 

    2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment 

    3.1. Risk Assessment 

        3.1.1. COVID-19 Crisis and Impact on Antidiabetics

        3.1.2. COVID-19 Impact Benchmark with Previous Crisis 

        3.1.3. Impact on Market Value (US$ Mn)

        3.1.4. Assessment by Key Countries

        3.1.5. Assessment by Key Market Segments

        3.1.6. Action Points and Recommendation for Suppliers

    3.2. Key Trends Impacting the Market

    3.3. Formulation and Product Development Trends

4. Market Background 

    4.1. Antidiabetics Market, by Key Countries

    4.2. Antidiabetics Market Opportunity Assessment (US$ Mn)

        4.2.1. Total Available Market

        4.2.2. Serviceable Addressable Market

        4.2.3. Serviceable Obtainable Market

    4.3. Market Scenario Forecast 

        4.3.1. Demand in optimistic Scenario

        4.3.2. Demand in Likely Scenario

        4.3.3. Demand in Conservative Scenario 

    4.4. Investment Feasibility Analysis

        4.4.1. Investment in Established Markets

            4.4.1.1. In Short Term

            4.4.1.2. In Long Term

        4.4.2. Investment in Emerging Markets

            4.4.2.1. In Short Term

            4.4.2.2. In Long Term

    4.5. Forecast Factors - Relevance & Impact

        4.5.1. Top Companies Historical Growth

        4.5.2. Growth in Automation, By Country

        4.5.3. Patch  Management Adoption Rate, By Country

    4.6. Market Dynamics

        4.6.1. Market Driving Factors and Impact Assessment

        4.6.2. Prominent Market Challenges and Impact Assessment

        4.6.3. Patch  Management Market Opportunities

        4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors 

    5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

    5.2. Banking on with Segments High Incremental Opportunity

    5.3. Peer Benchmarking 

6. Global Antidiabetics Market Demand Analysis 2015-2021 and Forecast, 2022-2032

    6.1. Historical Market Analysis, 2015-2021

    6.2. Current and Future Market Projections, 2022-2032

    6.3. Y-o-Y Growth Trend Analysis

7. Global Antidiabetics Market Value Analysis 2015-2021 and Forecast, 2022-2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032, By Product

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Product, 2015-2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032

        8.3.1. Insulin

            8.3.1.1. Rapid acting analog

            8.3.1.2. Long acting analog

            8.3.1.3. Premixed insulin

            8.3.1.4. Short acting analog

            8.3.1.5. Intermediate acting insulin

        8.3.2. Drug class

            8.3.2.1. Alpha glucosidase inhibitors

            8.3.2.2. Biguanides

            8.3.2.3. Sulphonylureas

            8.3.2.4. GLP-1 (Glucagon like peptide) agonists

            8.3.2.5. DPP-IV (Dipeptidyl Peptidase) inhibitors

            8.3.2.6. Meglitinides

            8.3.2.7. SGLT-II (Sodium Glucose Transport Proteins) inhibitors

            8.3.2.8. Thiazolidinedione

    8.4. Market Attractiveness Analysis By Product

9. Global Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032, By Patient Population

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Patient Population, 2015-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Patient Population, 2022-2032

        9.3.1. Pediatric

        9.3.2. Adult

        9.3.3. Geriatric

    9.4. Market Attractiveness Analysis By Patient Population

10. Global Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032, By Route of Administration

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032

        10.3.1. Insulin syringe/ Insulin pen 

        10.3.2. Insulin pump

        10.3.3. Intravenous infusion

        10.3.4. Oral

        10.3.5. Others

    10.4. Market Attractiveness Analysis By Route of Administration

11. Global Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032, By Region

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021

    11.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. Asia Pacific 

        11.3.5. Middle East and Africa (MEA)

    11.4. Market Attractiveness Analysis By Region

12. North America Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032

    12.1. Introduction

    12.2. Pricing Analysis

    12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    12.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        12.4.1. By Country

            12.4.1.1. U.S.

            12.4.1.2. Canada

            12.4.1.3. Rest of North America

        12.4.2. By Product

        12.4.3. By Route of Administration

        12.4.4. By Patient Population

    12.5. Market Attractiveness Analysis

        12.5.1. By Country

        12.5.2. By Product

        12.5.3. By Route of Administration

        12.5.4. By Patient Population

13. Latin America Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    13.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        13.4.1. By Country

            13.4.1.1. Brazil

            13.4.1.2. Mexico

            13.4.1.3. Rest of Latin America

        13.4.2. By Product

        13.4.3. By Route of Administration

        13.4.4. By Patient Population

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Product

        13.5.3. By Route of Administration

        13.5.4. By Patient Population

14. Europe Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    14.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        14.4.1. By Country

            14.4.1.1. Germany

            14.4.1.2. France

            14.4.1.3. U.K.

            14.4.1.4. Italy

            14.4.1.5. Benelux

            14.4.1.6. Nordic Countries

            14.4.1.7. Rest of Europe

        14.4.2. By Product

        14.4.3. By Route of Administration

        14.4.4. By Patient Population

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Product

        14.5.3. By Route of Administration

        14.5.4. By Patient Population

15. Asia Pacific Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    15.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        15.4.1. By Country

            15.4.1.1. China

            15.4.1.2. Japan

            15.4.1.3. South Korea

            15.4.1.4. Rest of Asia Pacific

        15.4.2. By Product

        15.4.3. By Route of Administration

        15.4.4. By Patient Population

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Product

        15.5.3. By Route of Administration

        15.5.4. By Patient Population

16. Middle East and Africa Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    16.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        16.4.1. By Country

            16.4.1.1. GCC Countries

            16.4.1.2. South Africa

            16.4.1.3. Turkey

            16.4.1.4. Rest of Middle East and Africa

        16.4.2. By Product

        16.4.3. By Route of Administration

        16.4.4. By Patient Population

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Product

        16.5.3. By Route of Administration

        16.5.4. By Patient Population

17. Key Countries Antidiabetics Market Analysis 2015-2021 and Forecast 2022-2032

    17.1. Introduction

        17.1.1. Market Value Proportion Analysis, By Key Countries

        17.1.2. Global Vs. Country Growth Comparison

    17.2. US Antidiabetics Market Analysis

        17.2.1. Value Proportion Analysis by Market Taxonomy

        17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.2.2.1. By Product

            17.2.2.2. By Route of Administration

            17.2.2.3. By Patient Population

    17.3. Canada Antidiabetics Market Analysis

        17.3.1. Value Proportion Analysis by Market Taxonomy

        17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.3.2.1. By Product

            17.3.2.2. By Route of Administration

            17.3.2.3. By Patient Population

    17.4. Mexico Antidiabetics Market Analysis

        17.4.1. Value Proportion Analysis by Market Taxonomy

        17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.4.2.1. By Product

            17.4.2.2. By Route of Administration

            17.4.2.3. By Patient Population

    17.5. Brazil Antidiabetics Market Analysis

        17.5.1. Value Proportion Analysis by Market Taxonomy

        17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.5.2.1. By Product

            17.5.2.2. By Route of Administration

            17.5.2.3. By Patient Population

    17.6. Germany Antidiabetics Market Analysis

        17.6.1. Value Proportion Analysis by Market Taxonomy

        17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.6.2.1. By Product

            17.6.2.2. By Route of Administration

            17.6.2.3. By Patient Population

    17.7. France Antidiabetics Market Analysis

        17.7.1. Value Proportion Analysis by Market Taxonomy

        17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.7.2.1. By Product

            17.7.2.2. By Route of Administration

            17.7.2.3. By Patient Population

    17.8. Italy Antidiabetics Market Analysis

        17.8.1. Value Proportion Analysis by Market Taxonomy

        17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.8.2.1. By Product

            17.8.2.2. By Route of Administration

            17.8.2.3. By Patient Population

    17.9. BENELUX Antidiabetics Market Analysis

        17.9.1. Value Proportion Analysis by Market Taxonomy

        17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.9.2.1. By Product

            17.9.2.2. By Route of Administration

            17.9.2.3. By Patient Population

    17.10. UK Antidiabetics Market Analysis

        17.10.1. Value Proportion Analysis by Market Taxonomy

        17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.10.2.1. By Product

            17.10.2.2. By Route of Administration

            17.10.2.3. By Patient Population

    17.11. Nordic Countries Antidiabetics Market Analysis

        17.11.1. Value Proportion Analysis by Market Taxonomy

        17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.11.2.1. By Product

            17.11.2.2. By Route of Administration

            17.11.2.3. By Patient Population

    17.12. China Antidiabetics Market Analysis

        17.12.1. Value Proportion Analysis by Market Taxonomy

        17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.12.2.1. By Product

            17.12.2.2. By Route of Administration

            17.12.2.3. By Patient Population

    17.13. Japan Antidiabetics Market Analysis

        17.13.1. Value Proportion Analysis by Market Taxonomy

        17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.13.2.1. By Product

            17.13.2.2. By Route of Administration

            17.13.2.3. By Patient Population

    17.14. South Korea Antidiabetics Market Analysis

        17.14.1. Value Proportion Analysis by Market Taxonomy

        17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.14.2.1. By Product

            17.14.2.2. By Route of Administration

            17.14.2.3. By Patient Population

    17.15. GCC Countries Antidiabetics Market Analysis

        17.15.1. Value Proportion Analysis by Market Taxonomy

        17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.15.2.1. By Product

            17.15.2.2. By Route of Administration

            17.15.2.3. By Patient Population

    17.16. South Africa Antidiabetics Market Analysis

        17.16.1. Value Proportion Analysis by Market Taxonomy

        17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.16.2.1. By Product

            17.16.2.2. By Route of Administration

            17.16.2.3. By Patient Population

    17.17. Turkey Antidiabetics Market Analysis

        17.17.1. Value Proportion Analysis by Market Taxonomy

        17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            17.17.2.1. By Product

            17.17.2.2. By Route of Administration

            17.17.2.3. By Patient Population

        17.17.3. Competition Landscape and Player Concentration in the Country

18. Market Structure Analysis

    18.1. Market Analysis by Tier of Companies 

    18.2. Market Concentration

    18.3. Market Share Analysis of Top Players

    18.4. Market Presence Analysis

        18.4.1. By Regional footprint of Players

        18.4.2. Product footprint by Players

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Competition Deep Dive 

        19.3.1. AstraZeneca

            19.3.1.1. Overview

            19.3.1.2. Product Portfolio

            19.3.1.3. Sales Footprint

            19.3.1.4. Strategy Overview

        19.3.2. Bayer Corporation

            19.3.2.1. Overview

            19.3.2.2. Product Portfolio

            19.3.2.3. Sales Footprint

            19.3.2.4. Strategy Overview

        19.3.3. Boehringer Ingelheim

            19.3.3.1. Overview

            19.3.3.2. Product Portfolio

            19.3.3.3. Sales Footprint

            19.3.3.4. Strategy Overview

        19.3.4. Bristol-Myers Squibb

            19.3.4.1. Overview

            19.3.4.2. Product Portfolio

            19.3.4.3. Sales Footprint

            19.3.4.4. Strategy Overview

        19.3.5. Eli Lilly

            19.3.5.1. Overview

            19.3.5.2. Product Portfolio

            19.3.5.3. Sales Footprint

            19.3.5.4. Strategy Overview

        19.3.6. Halozyme Therapeutics

            19.3.6.1. Overview

            19.3.6.2. Product Portfolio

            19.3.6.3. Sales Footprint

            19.3.6.4. Strategy Overview

        19.3.7. Johnson & Johnson

            19.3.7.1. Overview

            19.3.7.2. Product Portfolio

            19.3.7.3. Sales Footprint

            19.3.7.4. Strategy Overview

        19.3.8. Merck & Co. Inc.

            19.3.8.1. Overview

            19.3.8.2. Product Portfolio

            19.3.8.3. Sales Footprint

            19.3.8.4. Strategy Overview

        19.3.9. Novartis AG

            19.3.9.1. Overview

            19.3.9.2. Product Portfolio

            19.3.9.3. Sales Footprint

            19.3.9.4. Strategy Overview

        19.3.10. Novo Nordisk

            19.3.10.1. Overview

            19.3.10.2. Product Portfolio

            19.3.10.3. Sales Footprint

            19.3.10.4. Strategy Overview

        19.3.11. Oramed Pharmaceuticals Inc.

            19.3.11.1. Overview

            19.3.11.2. Product Portfolio

            19.3.11.3. Sales Footprint

            19.3.11.4. Strategy Overview

        19.3.12. Pfizer

            19.3.12.1. Overview

            19.3.12.2. Product Portfolio

            19.3.12.3. Sales Footprint

            19.3.12.4. Strategy Overview

        19.3.13. Sanofi

            19.3.13.1. Overview

            19.3.13.2. Product Portfolio

            19.3.13.3. Sales Footprint

            19.3.13.4. Strategy Overview

        19.3.14. Takeda Pharmaceutical

            19.3.14.1. Overview

            19.3.14.2. Product Portfolio

            19.3.14.3. Sales Footprint

            19.3.14.4. Strategy Overview

20. Assumptions and Acronyms Used

21. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Antidiabetics Market Value (US$ Mn), By Product, 2015 – 2021

Table 2: Global Antidiabetics Market Value (US$ Mn), By Product, 2022 – 2032

Table 3: Global Antidiabetics Market Value (US$ Mn), By Route of Administration, 2015 – 2021

Table 4: Global Antidiabetics Market Value (US$ Mn), By Route of Administration, 2022 – 2032

Table 5: Global Antidiabetics Market Value (US$ Mn), By Patient Population, 2015 – 2021

Table 6: Global Antidiabetics Market Value (US$ Mn), By Patient Population, 2022 – 2032

Table 7: Global Antidiabetics Market, By Region, 2015 – 2021

Table 8: Global Antidiabetics Market, By Region, 2022 – 2032

Table 9: North America Antidiabetics Market Value (US$ Mn), By Product, 2015 – 2021

Table 10: North America Antidiabetics Market Value (US$ Mn), By Product, 2022 – 2032

Table 11: North America Antidiabetics Market Value (US$ Mn), By Route of Administration, 2015 – 2021

Table 12: North America Antidiabetics Market Value (US$ Mn), By Route of Administration, 2022 – 2032

Table 13: North America Antidiabetics Market Value (US$ Mn), By Patient Population, 2015 – 2021

Table 14: North America Antidiabetics Market Value (US$ Mn), By Patient Population, 2022 – 2032

Table 15: North America Antidiabetics Market, By Country, 2015 – 2021

Table 16: North America Antidiabetics Market, By Country, 2022 – 2032

Table 17: Latin America Antidiabetics Market Value (US$ Mn), By Product, 2015 – 2021

Table 18: Latin America Antidiabetics Market Value (US$ Mn), By Product, 2022 – 2032

Table 19: Latin America Antidiabetics Market Value (US$ Mn), By Route of Administration, 2015 – 2021

Table 20: Latin America Antidiabetics Market Value (US$ Mn), By Route of Administration, 2022 – 2032

Table 21: Latin America Antidiabetics Market Value (US$ Mn), By Patient Population, 2015 – 2021

Table 22: Latin America Antidiabetics Market Value (US$ Mn), By Patient Population, 2022 – 2032

Table 23: Latin America Antidiabetics Market, By Country, 2015 – 2021

Table 24: Latin America Antidiabetics Market, By Country, 2022 – 2032

Table 25: Europe Antidiabetics Market Value (US$ Mn), By Product, 2015 – 2021

Table 26: Europe Antidiabetics Market Value (US$ Mn), By Product, 2022 – 2032

Table 27: Europe Antidiabetics Market Value (US$ Mn), By Route of Administration, 2015 – 2021

Table 28: Europe Antidiabetics Market Value (US$ Mn), By Route of Administration, 2022 – 2032

Table 29: Europe Antidiabetics Market Value (US$ Mn), By Patient Population, 2015 – 2021

Table 30: Europe Antidiabetics Market Value (US$ Mn), By Patient Population, 2022 – 2032

Table 31: Europe Antidiabetics Market, By Country, 2015 – 2021

Table 32: Europe Antidiabetics Market, By Country, 2022 – 2032

Table 33: Asia Pacific Antidiabetics Market Value (US$ Mn), By Product, 2015 – 2021

Table 34: Asia Pacific Antidiabetics Market Value (US$ Mn), By Product, 2022 – 2032

Table 35: Asia Pacific Antidiabetics Market Value (US$ Mn), By Route of Administration, 2015 – 2021

Table 36: Asia Pacific Antidiabetics Market Value (US$ Mn), By Route of Administration, 2022 – 2032

Table 37: Asia Pacific Antidiabetics Market Value (US$ Mn), By Patient Population, 2015 – 2021

Table 38: Asia Pacific Antidiabetics Market Value (US$ Mn), By Patient Population, 2022 – 2032

Table 39: Asia Pacific Antidiabetics Market, By Country, 2015 – 2021

Table 40: Asia Pacific Antidiabetics Market, By Country, 2022 – 2032

Table 41: MEA Antidiabetics Market Value (US$ Mn), By Product, 2015 – 2021

Table 42: MEA Antidiabetics Market Value (US$ Mn), By Product, 2022 – 2032

Table 43: MEA Antidiabetics Market Value (US$ Mn), By Route of Administration, 2015 – 2021

Table 44: MEA Antidiabetics Market Value (US$ Mn), By Route of Administration, 2022 – 2032

Table 45: MEA Antidiabetics Market Value (US$ Mn), By Patient Population, 2015 – 2021

Table 46: MEA Antidiabetics Market Value (US$ Mn), By Patient Population, 2022 – 2032

Table 47: MEA Antidiabetics Market, By Country, 2015 – 2021

Table 48: MEA Antidiabetics Market, By Country, 2022 – 2032

Table 49: Global Antidiabetics Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 50: Global Antidiabetics Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 51: Global Antidiabetics Market Incremental $ Opportunity, By Patient Population, 2015 - 2021

Table 52: Global Antidiabetics Market Incremental $ Opportunity, By Region, 2022 – 2032

Table 53: North America Antidiabetics Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 54: North America Antidiabetics Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 55: North America Antidiabetics Market Incremental $ Opportunity, By Patient Population, 2015 – 2021

Table 56: North America Antidiabetics Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 57: Latin America Antidiabetics Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 58: Latin America Antidiabetics Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 59: Latin America Antidiabetics Market Incremental $ Opportunity, By Patient Population, 2015 - 2021

Table 60: Latin America Antidiabetics Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 61: Europe Antidiabetics Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 62: Europe Antidiabetics Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 63: Europe Antidiabetics Market Incremental $ Opportunity, By Patient Population, 2015 - 2021

Table 64: Europe Antidiabetics Market Incremental $ Opportunity, By Country, 2022 - 2032

Table 65: Asia Pacific Antidiabetics Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 66: Asia Pacific Antidiabetics Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 67: Asia Pacific Antidiabetics Market Incremental $ Opportunity, By Patient Population, 2015 - 2021

Table 68: Asia Pacific Antidiabetics Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 69: MEA Antidiabetics Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 70: MEA Antidiabetics Market Incremental $ Opportunity, By Route of Administration, 2022 – 2032

Table 71: MEA Antidiabetics Market Incremental $ Opportunity, By Patient Population, 2015 - 2021

Table 72: MEA Antidiabetics Market Incremental $ Opportunity, By Country, 2022 - 2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 1: Global Antidiabetics Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 2: Global Antidiabetics Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn

Figure 3: Global Antidiabetics Market Share, By Product, 2022 & 2032

Figure 4: Global Antidiabetics Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 5: Global Antidiabetics Market Attractiveness Index, By Product – 2022-2032

Figure 6: Global Antidiabetics Market Share, By Route of Administration, 2022 & 2032

Figure 7: Global Antidiabetics Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 8: Global Antidiabetics Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 9: Global Antidiabetics Market Share, By Patient Population, 2022 & 2032

Figure 10: Global Antidiabetics Market Y-o-Y Growth Projections, By Patient Population – 2022-2032

Figure 11: Global Antidiabetics Market Attractiveness Index, By Patient Population – 2022-2032

Figure 12: Global Antidiabetics Market Share, By Region, 2022 & 2032

Figure 13: Global Antidiabetics Market Y-o-Y Growth Projections, By Region – 2022-2032

Figure 14: Global Antidiabetics Market Attractiveness Index, By Region – 2022-2032

Figure 15: North America Antidiabetics Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 16: North America Antidiabetics Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032),US$ Mn

Figure 17: North America Antidiabetics Market Share, By Product, 2022 & 2032

Figure 18: North America Antidiabetics Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 19: North America Antidiabetics Market Attractiveness Index, By Product – 2022-2032

Figure 20: North America Antidiabetics Market Share, By Route of Administration, 2022 & 2032

Figure 21: North America Antidiabetics Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 22: North America Antidiabetics Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 23: North America Antidiabetics Market Share, By Patient Population, 2022 & 2032

Figure 24: North America Antidiabetics Market Y-o-Y Growth Projections, By Patient Population – 2022-2032

Figure 25: North America Antidiabetics Market Attractiveness Index, By Patient Population – 2022-2032

Figure 26: North America Antidiabetics Market Share, By Country, 2022 & 2032

Figure 27: North America Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 28: North America Market Attractiveness Index, By Country – 2022-2032

Figure 29: Latin America Antidiabetics Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 30: Latin America Antidiabetics Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 31: Latin America Antidiabetics Market Share, By Product, 2022 & 2032

Figure 32: Latin America Antidiabetics Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 33: Latin America Antidiabetics Market Attractiveness Index, By Product – 2022-2032

Figure 34: Latin America Antidiabetics Market Share, By Route of Administration, 2022 & 2032

Figure 35: Latin America Antidiabetics Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 36: Latin America Antidiabetics Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 37: Latin America Antidiabetics Market Share, By Patient Population, 2022 & 2032

Figure 38: Latin America Antidiabetics Market Y-o-Y Growth Projections, By Patient Population – 2022-2032

Figure 39: Latin America Antidiabetics Market Attractiveness Index, By Patient Population – 2022-2032

Figure 40: Latin America Antidiabetics Market Share, By Country, 2022 & 2032

Figure 41: Latin America Antidiabetics Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 42: Latin America Antidiabetics Market Attractiveness Index, By Country – 2022-2032

Figure 43: Europe Antidiabetics Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 44: Europe Antidiabetics Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 45: Europe Antidiabetics Market Share, By Product, 2022 & 2032

Figure 46: Europe Antidiabetics Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 47: Europe Antidiabetics Market Attractiveness Index, By Product – 2022-2032

Figure 48: Europe Antidiabetics Market Share, By Route of Administration, 2022 & 2032

Figure 49: Europe Antidiabetics Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 50: Europe Antidiabetics Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 51: Europe Antidiabetics Market Share, By Patient Population, 2022 & 2032

Figure 52: Europe Antidiabetics Market Y-o-Y Growth Projections, By Patient Population – 2022-2032

Figure 53: Europe Antidiabetics Market Attractiveness Index, By Patient Population – 2022-2032

Figure 54: Europe Antidiabetics Market Share, By Country, 2022 & 2032

Figure 55: Europe Antidiabetics Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 56: Europe Antidiabetics Market Attractiveness Index, By Country – 2022-2032

Figure 57: MEA Antidiabetics Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 58: MEA Antidiabetics Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 59: MEA Antidiabetics Market Share, By Product, 2022 & 2032

Figure 60: MEA Antidiabetics Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 61: MEA Antidiabetics Market Attractiveness Index, By Product – 2022-2032

Figure 62: MEA Antidiabetics Market Share, By Route of Administration, 2022 & 2032

Figure 63: MEA Antidiabetics Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 64: MEA Antidiabetics Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 65: MEA Antidiabetics Market Share, By Patient Population, 2022 & 2032

Figure 66: MEA Antidiabetics Market Y-o-Y Growth Projections, By Patient Population – 2022-2032

Figure 67: MEA Antidiabetics Market Attractiveness Index, By Patient Population – 2022-2032

Figure 68: MEA Antidiabetics Market Share, By Country, 2022 & 2032

Figure 69: MEA Antidiabetics Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 70: MEA Antidiabetics Market Attractiveness Index, By Country – 2022-2032

Figure 71: Asia Pacific Antidiabetics Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 72: Asia Pacific Antidiabetics Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 73: Asia Pacific Antidiabetics Market Share, By Product, 2022 & 2032

Figure 74: Asia Pacific Antidiabetics Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 75: Asia Pacific Antidiabetics Market Attractiveness Index, By Product – 2022-2032

Figure 76: Asia Pacific Antidiabetics Market Share, By Route of Administration, 2022 & 2032

Figure 77: Asia Pacific Antidiabetics Market Y-o-Y Growth Projections, By Route of Administration – 2022-2032

Figure 78: Asia Pacific Antidiabetics Market Attractiveness Index, By Route of Administration – 2022-2032

Figure 79: Asia Pacific Antidiabetics Market Share, By Patient Population, 2022 & 2032

Figure 80: Asia Pacific Antidiabetics Market Y-o-Y Growth Projections, By Patient Population – 2022-2032

Figure 81: Asia Pacific Antidiabetics Market Attractiveness Index, By Patient Population – 2022-2032

Figure 82: Asia Pacific Antidiabetics Market Share, By Country, 2022 & 2032

Figure 83: Asia Pacific Antidiabetics Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 84: Asia Pacific Antidiabetics Market Attractiveness Index, By Country – 2022-2032

Figure 85: US Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 86: US Antidiabetics Market Share, By Product, 2021

Figure 87: US Antidiabetics Market Share, By Route of Administration, 2021

Figure 88: US Antidiabetics Market Share, By Patient Population, 2021

Figure 89: Canada Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 90: Canada Antidiabetics Market Share, By Product, 2021

Figure 91: Canada Antidiabetics Market Share, By Route of Administration, 2021

Figure 92: Canada Antidiabetics Market Share, By Patient Population, 2021

Figure 93: Brazil Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 94: Brazil Antidiabetics Market Share, By Product, 2021

Figure 95: Brazil Antidiabetics Market Share, By Route of Administration, 2021

Figure 96: Brazil Antidiabetics Market Share, By Patient Population, 2021

Figure 97: Mexico Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 98: Mexico Antidiabetics Market Share, By Product, 2021

Figure 99: Mexico Antidiabetics Market Share, By Route of Administration, 2021

Figure 100: Mexico Antidiabetics Market Share, By Patient Population, 2021

Figure 101: Germany Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 102: Germany Antidiabetics Market Share, By Product, 2021

Figure 103: Germany Antidiabetics Market Share, By Route of Administration, 2021

Figure 104: Germany Antidiabetics Market Share, By Patient Population, 2021

Figure 105: U.K. Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 106: U.K. Antidiabetics Market Share, By Product, 2021

Figure 107: U.K. Antidiabetics Market Share, By Route of Administration, 2021

Figure 108: U.K. Antidiabetics Market Share, By Patient Population, 2021

Figure 109: France Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 110: France Antidiabetics Market Share, By Product, 2021

Figure 111: France Antidiabetics Market Share, By Route of Administration, 2021

Figure 112: France Antidiabetics Market Share, By Patient Population, 2021

Figure 113: Italy Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 114: Italy Antidiabetics Market Share, By Product, 2021

Figure 115: Italy Antidiabetics Market Share, By Route of Administration, 2021

Figure 116: Italy Antidiabetics Market Share, By Patient Population, 2021

Figure 117: BENELUX Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 118: BENELUX Antidiabetics Market Share, By Product, 2021

Figure 119: BENELUX Antidiabetics Market Share, By Route of Administration, 2021

Figure 120: BENELUX Antidiabetics Market Share, By Patient Population, 2021

Figure 121: Nordic Countries Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 122: Nordic Countries Antidiabetics Market Share, By Product, 2021

Figure 123: Nordic Countries Antidiabetics Market Share, By Route of Administration, 2021

Figure 124: Nordic Countries Antidiabetics Market Share, By Patient Population, 2021

Figure 125: China Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 126: China Antidiabetics Market Share, By Product, 2021

Figure 127: China Antidiabetics Market Share, By Route of Administration, 2021

Figure 128: China Antidiabetics Market Share, By Patient Population, 2021

Figure 129: Japan Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 130: Japan Antidiabetics Market Share, By Product, 2021

Figure 131: Japan Antidiabetics Market Share, By Route of Administration, 2021

Figure 132: Japan Antidiabetics Market Share, By Patient Population, 2021

Figure 133: South Korea Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 134: South Korea Antidiabetics Market Share, By Product, 2021

Figure 135: South Korea Antidiabetics Market Share, By Route of Administration, 2021

Figure 136: South Korea Antidiabetics Market Share, By Patient Population, 2021

Figure 137: GCC Countries Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 138: GCC Countries Antidiabetics Market Share, By Product, 2021

Figure 139: GCC Countries Antidiabetics Market Share, By Route of Administration, 2021

Figure 140: GCC Countries Antidiabetics Market Share, By Patient Population, 2021

Figure 141: South Africa Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 142: South Africa Antidiabetics Market Share, By Product, 2021

Figure 143: South Africa Antidiabetics Market Share, By Route of Administration, 2021

Figure 144: South Africa Antidiabetics Market Share, By Patient Population, 2021

Figure 145: Turkey Antidiabetics Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 146: Turkey Antidiabetics Market Share, By Product, 2021

Figure 147: Turkey Antidiabetics Market Share, By Route of Administration, 2021

Figure 148: Turkey Antidiabetics Market Share, By Patient Population, 2021

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Diabetic Macular Edema Market

Published : July 2017

Healthcare

Diabetic Nephropathy Market

Published : December 2016

Healthcare

Diabetic Retinopathy Treatment Market

Published : March 2016

Healthcare

Diabetic Shoes Market

Published : February 2022

Google translate